Kristian Reich

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.3K citations

Immunology, Clinical Trials, Clinical Dermatology +7

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Kristian Reich, Frank O. Nestlé, Kim Papp et al. · The Lancet · 2005 · 1K citations

Infliximab Induction, Systemic Treatment, Phase Iii +7

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich et al. · Archives of Dermatological Research · 2010 · 868 citations · Full text

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 818 citations · Full text